Equities research analysts forecast that Sanofi SA (NYSE:SNY) will report earnings of $0.68 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Sanofi’s earnings. The highest EPS estimate is $0.71 and the lowest is $0.66. Sanofi posted earnings of $0.67 per share during the same quarter last year, which would suggest a positive year over year growth rate of 1.5%. The firm is expected to announce its next quarterly earnings report before the market opens on Wednesday, February 7th.
According to Zacks, analysts expect that Sanofi will report full-year earnings of $3.34 per share for the current year, with EPS estimates ranging from $3.18 to $3.45. For the next financial year, analysts anticipate that the company will post earnings of $3.42 per share, with EPS estimates ranging from $3.24 to $3.66. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Sanofi.
Sanofi (NYSE:SNY) last released its quarterly earnings results on Thursday, November 2nd. The company reported $1.00 EPS for the quarter, meeting analysts’ consensus estimates of $1.00. The business had revenue of $10.63 billion during the quarter, compared to analyst estimates of $10.93 billion. Sanofi had a return on equity of 25.19% and a net margin of 25.44%.
Several hedge funds have recently bought and sold shares of the business. Cullinan Associates Inc. grew its holdings in shares of Sanofi by 15.1% during the 4th quarter. Cullinan Associates Inc. now owns 91,150 shares of the company’s stock worth $3,919,000 after acquiring an additional 11,950 shares during the period. E&G Advisors LP grew its holdings in shares of Sanofi by 6.3% during the 4th quarter. E&G Advisors LP now owns 23,625 shares of the company’s stock worth $1,016,000 after acquiring an additional 1,400 shares during the period. Clean Yield Group grew its holdings in shares of Sanofi by 52.4% during the 4th quarter. Clean Yield Group now owns 61,352 shares of the company’s stock worth $2,638,000 after acquiring an additional 21,095 shares during the period. BLB&B Advisors LLC grew its holdings in shares of Sanofi by 36.8% during the 4th quarter. BLB&B Advisors LLC now owns 5,573 shares of the company’s stock worth $240,000 after acquiring an additional 1,500 shares during the period. Finally, Beacon Financial Group grew its holdings in shares of Sanofi by 12.5% during the 4th quarter. Beacon Financial Group now owns 105,488 shares of the company’s stock worth $4,536,000 after acquiring an additional 11,761 shares during the period. Hedge funds and other institutional investors own 9.08% of the company’s stock.
Sanofi (NYSE SNY) traded up $0.09 on Friday, reaching $44.60. The company’s stock had a trading volume of 1,897,864 shares, compared to its average volume of 1,290,000. The company has a market cap of $112,600.00, a price-to-earnings ratio of 20.18, a price-to-earnings-growth ratio of 2.43 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. Sanofi has a fifty-two week low of $39.42 and a fifty-two week high of $50.65.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/21/0-68-earnings-per-share-expected-for-sanofi-sa-sny-this-quarter.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.